circadian rhythm raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-02 and is reviewed periodically as new material appears.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
== History == In 2013, trastuzumab emtansine was approved in the United States for the treatment of adults with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Referred to as T-DM1 during clinical research, trastuzumab emtansine was reviewed under the FDA's priority review program. The safety and effectiveness of trastuzumab emtansine were evaluated in a clinical study of 991 patients randomly assigned to receive trastuzumab emtansine or lapatinib plus capecitabine, another chemotherapy drug. Patients received treatment until either the cancer progressed or the side effects became intolerable. The study was designed to measure progression-free survival, the length of time patients lived without the cancer progressing, and overall survival, the length of time patients lived before death. Results showed that patients treated with trastuzumab emtansine had a median progression-free survival of 9.6 months compared to 6.4 months in patients treated with lapatinib plus capecitabine. The median overall survival was 30.9 months in the trastuzumab emtansine group and 25.1 months in the lapatinib plus capecitabine group. The U.S. Food and Drug Administration (FDA) approved trastuzumab emtansine in February 2013, and granted the application for Kadcyla to Genentech. The FDA granted the application for trastuzumab emtansine priority review and breakthrough therapy designations. In 2013, trastuzumab emtansine was approved in the UK, and the EU.
== Clinical significance == Mutations in and decreased expression of this protein are associated with amyotrophic lateral sclerosis (ALS). The drug riluzole approved for the treatment of ALS upregulates EAAT2. Ceftriaxone, an antibiotic, has been shown to induce/enhance the expression of EAAT2, resulting in reduced glutamate activity. Ceftriaxone has been shown to reduce the development and expression of tolerance to opiates and other drugs of abuse. EAAT2 may possess an important role in drug addiction and tolerance to addictive drugs. Upregulation of EAAT2 (GLT-1) causes impairment of prepulse inhibition, a sensory gating deficit present in schizophrenics and schizophrenia animal models. Some antipsychotics have been shown to reduce the expression of EAAT2.
The South African Border War, also known as the Namibian War of Independence, and sometimes denoted in South Africa as the Angolan Bush War, was a largely asymmetric conflict that occurred in Namibia (then South West Africa), Zambia, and Angola from 26 August 1966 to 21 March 1990. It was fought between the South African Defence Force (SADF) and the People's Liberation Army of Namibia (PLAN), an armed wing of the South West African People's Organisation (SWAPO). The South African Border War was closely intertwined with the Angolan Civil War.
Sources: en.wikipedia.org
==== 2023: Transferring to Miami ==== McCormick transferred out of Oregon in 2023, entering the University of Miami. He enrolled in a postbaccalaureate program, during which he performs undergraduate coursework. He joined the Hurricanes for their 2023 season. During that season, McCormick was a starter for the Hurricanes in eleven games, including the 2023 Pinstripe Bowl, earning six receptions for 62 yards.
On 26 July, a mortar strike from Afghanistan on Zamchan in South Waziristan killed a woman and imjured two children. A TTP militant was killed in a skirmish in Regi Model town of Peshawar while two dead bodies of TTP militants were recovered from Bannu District. Militants attacked the Gandak border post of the 133 Wing of the SWS Brigade in Azam Warsak area of South Waziristan killing three FC soldiers. Two civilians were injured in a militant drone strike on Hadi village of Mirali. Two soldiers were killed and one was wounded in an IED attack in Spinwam. On 27 July, a quadcopter strike on a mosque in Birmal Tehsil killed a cleric and wounded two. A joint counterterrorism operation was started in the border hill tracts of Abdul Khel, Shah Hassan Khel, and Hayat Khel area of Lakki Marwat District forcing insurgents to flee while a senior TTP commander was also killed in the Wanda Semo area. An off-duty FC soldier was killed in the Dildar Garhi area of Charsadda District. On 28 July, a counter-terrorism operation was launched in the Shalkho Sar area of Swat following the abduction of a Village defense guard while four TTP militants and one Special Operations Team personnel were killed in an operation in the Matta area of Swat District. Insurgents blew up a mosque in the Lachi area of Kohat District. The operation continued in Lakki Marwat with two alleged underground militant bunker and equipment being destroyed. Three soldiers were killed and four wounded in a TTP ambush in the Shoi Khel area of Shawal tehsil.
On the other hand, the number of Japanese tourists declined after the exemption took effect. In addition, citizens of these countries will be allowed to use the electronic visa, which had been in effect before the unilateral exemption. The reinstatement of the visa requirement for tourists from the aforementioned countries, which was originally to occur starting in October 2023, was initially postponed to January 2024 and then to April 2024. Officially, the government declared that the measure sought not to harm tourism during the high season. In reality, the postponement resulted from the inability of local consulates to deal with the new demand, making it impossible for thousands of American and Canadian tourists to obtain visas in time to travel to Brazil. In 2024, Brazil reached a historic record in the entry of foreign tourists, with more than 6.6 million international travelers in the country. In 2025, the Brazilian passport ranked 16th among the 20 most powerful in the world according to the American consultancy Henley & Partners, while the international Passport Index ranking placed it 11th. Between January and September 2025, Brazil reached a historic record of 7 million tourists for the first time. According to Marcelo Freixo, president of Embratur, the record is the result of the government's effort to "rebuild Brazil's image in the world as a destination of diversity and sustainability".
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.